DE3218761C2 - - Google Patents

Info

Publication number
DE3218761C2
DE3218761C2 DE3218761A DE3218761A DE3218761C2 DE 3218761 C2 DE3218761 C2 DE 3218761C2 DE 3218761 A DE3218761 A DE 3218761A DE 3218761 A DE3218761 A DE 3218761A DE 3218761 C2 DE3218761 C2 DE 3218761C2
Authority
DE
Germany
Prior art keywords
withdrawal
treatment
caused
compound
nonapeptide
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE3218761A
Other languages
German (de)
English (en)
Other versions
DE3218761A1 (de
Inventor
Richard Raimund Dr. 7851 Inzlingen De Scherschlicht
Rene Prof. Chene-Bourg Ch Tissot
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
F Hoffmann La Roche AG
Original Assignee
F Hoffmann La Roche AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F Hoffmann La Roche AG filed Critical F Hoffmann La Roche AG
Publication of DE3218761A1 publication Critical patent/DE3218761A1/de
Application granted granted Critical
Publication of DE3218761C2 publication Critical patent/DE3218761C2/de
Granted legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Neurology (AREA)
  • Psychiatry (AREA)
  • Biomedical Technology (AREA)
  • Addiction (AREA)
  • Neurosurgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
DE3218761A 1981-05-21 1982-05-18 Nonapeptid zur behandlung von suchtmittelentzugserscheinungen Granted DE3218761A1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CH330681 1981-05-21

Publications (2)

Publication Number Publication Date
DE3218761A1 DE3218761A1 (de) 1982-12-16
DE3218761C2 true DE3218761C2 (cg-RX-API-DMAC10.html) 1993-05-06

Family

ID=4253131

Family Applications (1)

Application Number Title Priority Date Filing Date
DE3218761A Granted DE3218761A1 (de) 1981-05-21 1982-05-18 Nonapeptid zur behandlung von suchtmittelentzugserscheinungen

Country Status (11)

Country Link
US (2) US4444758A (cg-RX-API-DMAC10.html)
EP (1) EP0065747B1 (cg-RX-API-DMAC10.html)
JP (1) JPS5823630A (cg-RX-API-DMAC10.html)
AU (1) AU552547B2 (cg-RX-API-DMAC10.html)
CA (1) CA1188989A (cg-RX-API-DMAC10.html)
DE (1) DE3218761A1 (cg-RX-API-DMAC10.html)
IE (1) IE53395B1 (cg-RX-API-DMAC10.html)
IL (1) IL65782A (cg-RX-API-DMAC10.html)
IT (1) IT1152116B (cg-RX-API-DMAC10.html)
PH (1) PH17981A (cg-RX-API-DMAC10.html)
ZA (1) ZA823369B (cg-RX-API-DMAC10.html)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5486599A (en) * 1989-03-29 1996-01-23 The Board Of Trustees Of The Leland Stanford Junior University Construction and use of synthetic constructs encoding syndecan
US5486362A (en) * 1991-05-07 1996-01-23 Dynagen, Inc. Controlled, sustained release delivery system for treating drug dependency
US5403595A (en) * 1991-05-07 1995-04-04 Dynagen, Inc. Controlled, sustained release delivery system for smoking cessation
US5780051A (en) * 1992-04-02 1998-07-14 Dynagen, Inc. Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
US7220737B1 (en) 1997-09-04 2007-05-22 Novoneuron, Inc Noribogaine in the treatment of pain and drug addiction
ES2395268T3 (es) 1997-09-04 2013-02-11 Demerx, Inc. Noribogaína para el tratamiento del dolor y la drogadicción
AP2001002245A0 (en) * 1999-02-05 2001-09-30 Univ Manchester Regulation of anesthesia.
DE10014007A1 (de) * 2000-03-22 2001-10-11 Strathmann Ag & Co Neue Darreichungsformen für DSIP
RU2005128993A (ru) * 2005-09-08 2007-03-20 Общество С Ограниченной Ответственностью Исследовательский Центр "Комкон" (Ru) Средство для коррекции стресс-индуцируемых нейромедиаторных, нейроэндокринных и метаболических нарушений, а также способ профилактики и лечения сопутствующих им паталогических состояний
WO2009033814A2 (en) * 2007-09-11 2009-03-19 Mondobiotech Laboratories Ag Use of the peptide combination thymosin beta 4 and delta sleep inducing peptide as a therapeutic agent
US8765737B1 (en) 2010-05-11 2014-07-01 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US9394294B2 (en) 2010-05-11 2016-07-19 Demerx, Inc. Methods and compositions for preparing and purifying noribogaine
US8362007B1 (en) 2010-05-11 2013-01-29 Demerx, Inc. Substituted noribogaine
US8637648B1 (en) 2010-06-22 2014-01-28 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US8741891B1 (en) 2010-06-22 2014-06-03 Demerx, Inc. N-substituted noribogaine prodrugs
US8802832B2 (en) 2010-06-22 2014-08-12 Demerx, Inc. Compositions comprising noribogaine and an excipient to facilitate transport across the blood brain barrier
US9586954B2 (en) 2010-06-22 2017-03-07 Demerx, Inc. N-substituted noribogaine prodrugs
WO2012012764A1 (en) 2010-07-23 2012-01-26 Demerx, Inc. Noribogaine compositions
EP2481740B1 (en) 2011-01-26 2015-11-04 DemeRx, Inc. Methods and compositions for preparing noribogaine from voacangine
US9617274B1 (en) 2011-08-26 2017-04-11 Demerx, Inc. Synthetic noribogaine
WO2013085922A1 (en) 2011-12-09 2013-06-13 Demerx, Inc. Phosphate esters of noribogaine
US9150584B2 (en) 2012-01-25 2015-10-06 Demerx, Inc. Indole and benzofuran fused isoquinuclidene derivatives and processes for preparing them
EP2807168A4 (en) 2012-01-25 2015-10-14 Demerx Inc SYNTHETIC VOACANGINE
US9045481B2 (en) 2012-12-20 2015-06-02 Demerx, Inc. Substituted noribogaine
EP2934541A4 (en) 2012-12-20 2016-08-03 Demerx Inc NORIBOGAINE SUBSTITUTE
US8940728B2 (en) 2012-12-20 2015-01-27 Demerx, Inc. Substituted noribogaine
US9550789B2 (en) 2014-06-18 2017-01-24 Demerx, Inc. Halogenated indole and benzofuran derivatives of isoquinuclidene and processes for preparing them

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH634331A5 (de) * 1977-06-30 1983-01-31 Hoffmann La Roche Phosphorylierte nonapeptide und verfahren zu deren herstellung.

Also Published As

Publication number Publication date
US4496545A (en) 1985-01-29
IT8221072A0 (it) 1982-05-04
US4444758A (en) 1984-04-24
IT1152116B (it) 1986-12-31
IL65782A0 (en) 1982-08-31
EP0065747B1 (de) 1986-10-15
EP0065747A1 (de) 1982-12-01
AU8375682A (en) 1982-11-25
JPS5823630A (ja) 1983-02-12
ZA823369B (en) 1983-03-30
AU552547B2 (en) 1986-06-05
DE3218761A1 (de) 1982-12-16
IE821214L (en) 1982-11-21
IL65782A (en) 1985-08-30
CA1188989A (en) 1985-06-18
PH17981A (en) 1985-02-26
IE53395B1 (en) 1988-11-09
JPH0354089B2 (cg-RX-API-DMAC10.html) 1991-08-19

Similar Documents

Publication Publication Date Title
DE3218761C2 (cg-RX-API-DMAC10.html)
DE69012591T2 (de) Verwendung von Nikotin zur Herstellung eines Kit zur Behandlung von Krankheitszuständen, die auf eine Nikotinbehandlung ansprechen.
EP0680326B1 (de) Pharmazeutische formulierung zur behandlung der nicotinabhängigkeit
DE60019436T2 (de) Verwendung von nikotin oder derivaten davon und l-dopa in einem medikament zur behandlung von neurologischen erkrankungen, insbesondere der parkinson-erkrankung
DE69224069T2 (de) Pharmazeutisches kombinationspräparat, das ein uricosurisches mittel und einen excitatorischen aminosäure-antagonisten enthält
DE69529156T2 (de) Verwendung von amino-hydrierten chinazolinverbindungen und ihren derivaten zur entwöhnung bei drogenabhängigkeit
DE2856393A1 (de) Mittel zur behandlung des zentralnervensystems
EP0759295A1 (de) Verwendung von Adamantan-Derivaten zur Behandlung von Erkrankungen des Innenohrs
DE69027220T2 (de) Zusammensetzung und verfahren zur behandlung von schmerzvollen entzündlichen oder allergischen erkrankungen
DE3304246C2 (cg-RX-API-DMAC10.html)
EP0185210B1 (de) Verwendung von Dipeptidderivaten für die Herstellung von Arzneimitteln zur Behandlung von an amyotropher Lateralsklerose Erkrankten
DE3390116C2 (de) Verbesserte, Koffein enthaltende, analgetische und antiinflammatorische Mittel
DE69333014T2 (de) Verwendung von 4-aminopyridin zur behandlung von schmerz und spastik folgende einer verletzung des rückenmarks
DE4342174C1 (de) Transdermales therapeutisches System sowie ein Verfahren zur Herstellung eines transdermalen therapeutischen Systems zur kombinierten transdermalen Anwendung von Physostigmin und Scopolamin für die Prophylaxe und zur Vorbehandlung einer Vergiftung durch hochtoxische phosphororganische Nervengifte, insbesondere Soman und seine Verwendung
DE69024053T2 (de) Behandlung zur ermässigung von ödem und muskelschäden.
DE60017147T2 (de) Verwendung von gabab-rezeptor agonisten und deren pharmazeutisch akzeptierbaren derivate bei der therapie zur erhaltung von nikotinabstinenz bei nikotinabhängigen patienten
DE69800859T2 (de) Verwendung von Moxonidin zur Behandlung neuropathischer Schmerzen
DE3687575T2 (de) Verwendung von 6-methylen-6-desoxy-n-cyclopropylmethyl-14-hydroxydihydronormorphin.
DE2900203A1 (de) Krebshemmendes und krebsmetastasen verhinderndes arzneimittel
CH658595A5 (de) Retinoprotektor zur behandlung von augenerkrankungen.
DE69430427T2 (de) Verwendung von ropivacaine zur herstellung eines analgetikums mit minimaler motorischer blockade
DE69330638T2 (de) Verwendung von 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine zur herstrllung eines medikaments zur behandlung von bestimmten schmerzen und ödem
DE19726871C1 (de) Synergistisch wirkende Zusammensetzungen zur selektiven Bekämpfung von Tumorgewebe
EP0132595B1 (de) Tokolytisches Mittel
DE4028487A1 (de) Entzuendung- und schmerzhemmendes nervenmittel

Legal Events

Date Code Title Description
8110 Request for examination paragraph 44
8127 New person/name/address of the applicant

Owner name: F. HOFFMANN-LA ROCHE AG, BASEL, CH

8128 New person/name/address of the agent

Representative=s name: LEDERER, F., DIPL.-CHEM. DR., 8000 MUENCHEN RIEDER

D2 Grant after examination
8364 No opposition during term of opposition